VTGN logo

VTGN
VistaGen Therapeutics Inc

18,100
Mkt Cap
$156.54M
Volume
744,448.00
52W High
$5.14
52W Low
$1.90
PE Ratio
-2.68
VTGN Fundamentals
Price
$4.25
Prev Close
$3.95
Open
$3.99
50D MA
$4.16
Beta
1.38
Avg. Volume
758,019.63
EPS (Annual)
-$1.67
P/B
2.49
Rev/Employee
$8,526.32
Loading...
Loading...
News
all
press releases
VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above 50-Day Moving Average - Should You Sell?
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average - What's Next...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Vistagen Names Nick Tressler CFO
(RTTNews) - South San Francisco-based late clinical-stage biopharma company Vistagen Therapeutics, Inc. (VTGN) Monday announced the appointment of Nick Tressler as Chief Financial Officer...
Nasdaq News: Markets·12d ago
News Placeholder
Vistagen Appoints Nick Tressler as Chief Financial Officer
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·12d ago
News Placeholder
Vistagen Reports Findings on PH80s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·17d ago
News Placeholder
VistaGen Therapeutics (NASDAQ:VTGN) Releases Earnings Results, Misses Estimates By $0.03 EPS
VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·28d ago
News Placeholder
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5.88% and -59.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·30d ago
News Placeholder
Examining the Future: VistaGen Therapeutics's Earnings Outlook
read more...
Benzinga·1mo ago
News Placeholder
XOMA Royalty (XOMA) Reports Q3 Loss, Lags Revenue Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of -1,650.00% and -25.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...
Business Wire·1mo ago

Latest VTGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.